AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15181994 — intervention group
Group type: COMPARATOR
Intervention: Differential path-length spectroscopy (DPS) on normal bronchial mucosa
Number of subjects: 0
Study 11245451 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg of beta-carotene per day
Number of subjects: 264
Study 11245451 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 264
Study 9676666 — intervention group
Group type: EXPERIMENTAL
Intervention: Masked peer review
Number of subjects: 467
Study 9676666 — intervention group
Group type: EXPERIMENTAL
Intervention: Unmasked peer review
Number of subjects: 467
Study 9676666 — intervention group
Group type: EXPERIMENTAL
Intervention: Blinded peer review
Number of subjects: 467
Study 9676666 — intervention group
Group type: EXPERIMENTAL
Intervention: Unblinded peer review
Number of subjects: 467
Study 9676666 — intervention group
Group type: COMPARATOR
Intervention: All groups
Number of subjects: 467
Study 7761550 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulse-loading group received 150 and 200 mg of clomipramine (CMI) on 2 consecutive evenings followed by placebo for 8 days
Number of subjects: 32
Study 7761550 — intervention group
Group type: COMPARATOR
Intervention: Traditional dosing group began at 50 mg of CMI with gradual increases every second day until 200 mg was reached
Number of subjects: 32
Study 3073805 — intervention group
Group type: COMPARATOR
Intervention: Standard theophylline (300 mg twice daily)
Number of subjects: 40
Study 3073805 — intervention group
Group type: COMPARATOR
Intervention: Titrated theophylline (doses ranged from 300 mg to 700 mg twice daily)
Number of subjects: 40
Study 3073805 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 3073805 — intervention group
Group type: EXPERIMENTAL
Intervention: Titrated theophylline (for subgroup with titrated dose greater than standard)
Number of subjects: 40
Study 3073805 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline (general conclusion)
Number of subjects: 40
Study 31509614 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness (measured by Five Facet Mindfulness Questionnaire‐Short Form [FFMQ‐SF])
Number of subjects: 64
Study 31509614 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonreactivity facet of mindfulness
Number of subjects: 64
Study 31509614 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonjudging facet of mindfulness
Number of subjects: 64
Study 31509614 — intervention group
Group type: EXPERIMENTAL
Intervention: Describing facet of mindfulness
Number of subjects: 64
Study 31509614 — intervention group
Group type: EXPERIMENTAL
Intervention: Observing facet of mindfulness
Number of subjects: 64
Study 30951225 — intervention group
Group type: EXPERIMENTAL
Intervention: Retinol
Number of subjects: 0
Study 30951225 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycolic acid
Number of subjects: 0
Study 30951225 — intervention group
Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 0
Study 29191951 — intervention group
Group type: EXPERIMENTAL
Intervention: Active CPAP therapy
Number of subjects: 1105
Study 29191951 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP usage >4 h·night-1
Number of subjects: 1105
Study 25887970 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention for improving medication adherence and asthma control
Number of subjects: 55
Study 25887970 — intervention group
Group type: EXPERIMENTAL
Intervention: GPs perceiving good support from the research team
Number of subjects: 55
Study 25887970 — intervention group
Group type: EXPERIMENTAL
Intervention: Recruitment barriers at the level of GP, practice, patient, and study
Number of subjects: 55
Study 22311554 — intervention group
Group type: EXPERIMENTAL
Intervention: Heated Humidifier (HH)
Number of subjects: 52
Study 22311554 — intervention group
Group type: COMPARATOR
Intervention: Non-Heated Humidifier (non-HH)
Number of subjects: 52
Study 21487851 — intervention group
Group type: EXPERIMENTAL
Intervention: Celsior solution (CS)
Number of subjects: 102
Study 21487851 — intervention group
Group type: COMPARATOR
Intervention: University of Wisconsin solution (UW)
Number of subjects: 102
Study 18331614 — intervention group
Group type: EXPERIMENTAL
Intervention: Flupenthixol + Melitracen (F + M)
Number of subjects: 25
Study 18331614 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 16549964 — intervention group
Group type: EXPERIMENTAL
Intervention: CART and rofecoxib 25 mg bid
Number of subjects: 38
Study 16549964 — intervention group
Group type: EXPERIMENTAL
Intervention: CART and celecoxib 400 mg bid
Number of subjects: 38
Study 16549964 — intervention group
Group type: COMPARATOR
Intervention: CART only (without placebo)
Number of subjects: 38
Study 12704305 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified curriculum with Dynadjust Instrument training aid
Number of subjects: 39
Study 12704305 — intervention group
Group type: COMPARATOR
Intervention: Standard curriculum alone
Number of subjects: 39
Study 10924705 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional transcranial Doppler ultrasonography during maze testing
Number of subjects: 0
Study 10924705 — intervention group
Group type: EXPERIMENTAL
Intervention: Logistic regression analysis of ACA reactivity
Number of subjects: 0
Study 9194110 — intervention group
Group type: EXPERIMENTAL
Intervention: COMVAX (7.5 micrograms of PRP/5 micrograms of HBsAg in 0.5 ml)
Number of subjects: 882
Study 9194110 — intervention group
Group type: COMPARATOR
Intervention: P+R (PedvaxHIB and RECOMBIVAX HB)
Number of subjects: 882
Study 9194110 — intervention group
Group type: EXPERIMENTAL
Intervention: COMVAX
Number of subjects: 882
Study 9194110 — intervention group
Group type: COMPARATOR
Intervention: P+R
Number of subjects: 882
Study 1337466 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination chemotherapy regimen 1
Number of subjects: 188
Study 1337466 — intervention group
Group type: COMPARATOR
Intervention: Combination chemotherapy regimen 2
Number of subjects: 188
Study 3982238 — intervention group
Group type: EXPERIMENTAL
Intervention: Breakfast enriched in lard
Number of subjects: 0
Study 3982238 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard diets excluding lard
Number of subjects: 0
Study 3982238 — intervention group
Group type: EXPERIMENTAL
Intervention: Free choice diets
Number of subjects: 0
Study 30712747 — intervention group
Group type: EXPERIMENTAL
Intervention: Gua Sha therapy (n=25)
Number of subjects: 50
Study 30712747 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control (n=25)
Number of subjects: 50
Study 29501671 — intervention group
Group type: EXPERIMENTAL
Intervention: Montreal Imaging Stress Task (MIST)
Number of subjects: 60
Study 29501671 — intervention group
Group type: COMPARATOR
Intervention: Speech task
Number of subjects: 60
Study 29501671 — intervention group
Group type: COMPARATOR
Intervention: Stroop task
Number of subjects: 60
Study 29501671 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender-related differences
Number of subjects: 60
Study 27724922 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimised diary
Number of subjects: 33
Study 27724922 — intervention group
Group type: COMPARATOR
Intervention: Nonoptimised diary
Number of subjects: 33
Study 27724922 — intervention group
Group type: EXPERIMENTAL
Intervention: Both diaries
Number of subjects: 33
Study 24438512 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous bone marrow mesenchymal stem cells (MSC) delivered via intra-arterial injection
Number of subjects: 0
Study 24438512 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 22984506 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 3548
Study 22984506 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle modification
Number of subjects: 3548
Study 22984506 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3548
Study 22984506 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic variants
Number of subjects: 3548
Study 22984506 — intervention group
Group type: EXPERIMENTAL
Intervention: MADD
Number of subjects: 3548
Study 19448234 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mL of 0.5% ropivacaine with 0.5 microg/mL sufentanil (Group 1)
Number of subjects: 45
Study 19448234 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mL of 0.2% ropivacaine with 0.5 microg/mL sufentanil (Group 2)
Number of subjects: 45
Study 19448234 — intervention group
Group type: COMPARATOR
Intervention: 10 mL saline (Group 3)
Number of subjects: 45
Study 17092845 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpretation of spirometry and peak flow measurement by specialists
Number of subjects: 98
Study 17092845 — intervention group
Group type: COMPARATOR
Intervention: General practitioners' interpretation of spirometry and peak flow measurement
Number of subjects: 98
Study 14653084 — intervention group
Group type: COMPARATOR
Intervention: 10 ml saline (Group A)
Number of subjects: 175
Study 14653084 — intervention group
Group type: EXPERIMENTAL
Intervention: esmolol 0.5 mg/kg (Group B)
Number of subjects: 175
Study 14653084 — intervention group
Group type: EXPERIMENTAL
Intervention: esmolol 1.0 mg/kg (Group C)
Number of subjects: 175
Study 14653084 — intervention group
Group type: EXPERIMENTAL
Intervention: esmolol 1.5 mg/kg (Group D)
Number of subjects: 175
Study 14653084 — intervention group
Group type: EXPERIMENTAL
Intervention: esmolol 2.0 mg/kg (Group E)
Number of subjects: 175
Study 11045293 — intervention group
Group type: EXPERIMENTAL
Intervention: Vancomycin (1000 mg i.v. 12 hours before procedure)
Number of subjects: 265
Study 11045293 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefazolin (1000 mg i.v. 3 hours before procedure)
Number of subjects: 265
Study 11045293 — intervention group
Group type: COMPARATOR
Intervention: Control group (no antibiotics for at least one week before procedure)
Number of subjects: 265
Study 9186325 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical epirubicin (50 mg)
Number of subjects: 253
Study 9186325 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical epirubicin (80 mg)
Number of subjects: 253
Study 9186325 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical doxorubicin (50 mg)
Number of subjects: 253
Study 9186325 — intervention group
Group type: COMPARATOR
Intervention: Control (transurethral bladder tumor resection alone)
Number of subjects: 253
Study 1607691 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral erythromycin (250 mg twice a day)
Number of subjects: 186
Study 1607691 — intervention group
Group type: COMPARATOR
Intervention: Vitamin (one tablet daily)
Number of subjects: 186
Study 4029717 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous omeprazole 80 mg at 0900 and 40 mg at 1700
Number of subjects: 5
Study 4029717 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous omeprazole 80 mg at 0900 and 80 mg at 1700
Number of subjects: 5
Study 4029717 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous omeprazole 80 mg at 0900, 40 mg at 1700 and 40 mg at 0100
Number of subjects: 5
Study 4029717 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study 31791384 — intervention group
Group type: EXPERIMENTAL
Intervention: OROS-methylphenidate (Concerta XL) for 8 weeks, titrated over 5 weeks
Number of subjects: 200
Study 31791384 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 8 weeks, titrated over 5 weeks
Number of subjects: 200
Study 29188339 — intervention group
Group type: EXPERIMENTAL
Intervention: Best-practice diabetes care with additional evidence-based weight management programme (Counterweight-Plus)
Number of subjects: 298
Study 29188339 — intervention group
Group type: COMPARATOR
Intervention: Best-practice diabetes care alone
Number of subjects: 298
Study 27055398 — intervention group
Group type: EXPERIMENTAL
Intervention: IG-IMRT
Number of subjects: 431
Study 27055398 — intervention group
Group type: COMPARATOR
Intervention: 3D-CRT
Number of subjects: 431
Study 24708554 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 33
Study 24708554 — intervention group
Group type: COMPARATOR
Intervention: Prednisolone
Number of subjects: 33
Study 24708554 — intervention group
Group type: EXPERIMENTAL
Intervention: Pure focal distribution of demyelination
Number of subjects: 33
Study 24708554 — intervention group
Group type: COMPARATOR
Intervention: Non-focal distribution of demyelination
Number of subjects: 33
Study 24708554 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean median nerve sensory nerve conduction velocity (SNCV)
Number of subjects: 33
Study 21970545 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone 4 mg b.i.d. plus clomiphene citrate (CC) 100 mg on cycle days 3‐7
Number of subjects: 100
Study 21970545 — intervention group
Group type: COMPARATOR
Intervention: Clomiphene citrate (CC) only
Number of subjects: 100
Study 21970545 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone therapy
Number of subjects: 100
Study 20304845 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous annuloplasty rings
Number of subjects: 100
Study 20304845 — intervention group
Group type: COMPARATOR
Intervention: SJM Tailor flexible prosthesis
Number of subjects: 100
Study 18500437 — intervention group
Group type: EXPERIMENTAL
Intervention: Gold bead implantation at five acupuncture points around the knee
Number of subjects: 43
Study 18500437 — intervention group
Group type: COMPARATOR
Intervention: Needle insertion alone (Control)
Number of subjects: 43
Study 18500437 — intervention group
Group type: EXPERIMENTAL
Intervention: Gold bead implantation
Number of subjects: 43
Study 15812624 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosimendan (0.2 microg/kg per minute, n=15)
Number of subjects: 28
Study 15812624 — intervention group
Group type: COMPARATOR
Intervention: Dobutamine (5 microg/kg per minute, n=13)
Number of subjects: 28
Study 12356614 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture alone
Number of subjects: 141
Study 12356614 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 141
Study 12356614 — intervention group
Group type: EXPERIMENTAL
Intervention: Education alone
Number of subjects: 141
Study 12356614 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined acupuncture and education
Number of subjects: 141
Study 10338443 — intervention group
Group type: EXPERIMENTAL
Intervention: darifenacin 5 mg t.d.s.
Number of subjects: 6
Study 10338443 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 6
Study 8758748 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificial pneumothorax
Number of subjects: 57
Study 8758748 — intervention group
Group type: COMPARATOR
Intervention: Standard treatments with anti-tuberculous drugs (Control)
Number of subjects: 57
Study 1929764 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral group treatment program
Number of subjects: 65
Study 1929764 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacotherapy with phenelzine sulfate
Number of subjects: 65
Study 1929764 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacotherapy with alprazolam
Number of subjects: 65
Study 1929764 — intervention group
Group type: COMPARATOR
Intervention: Pill-placebo plus instructions for self-directed exposure to phobic stimuli
Number of subjects: 65
Study 1929764 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive measure
Number of subjects: 65
Study 7037163 — intervention group
Group type: EXPERIMENTAL
Intervention: FAMi (5‐FU, Adriamycin + mitomycin C)
Number of subjects: 181
Study 7037163 — intervention group
Group type: EXPERIMENTAL
Intervention: FAMe (5‐FU, Adriamycin + methyl‐CCNU)
Number of subjects: 181
Study 7037163 — intervention group
Group type: EXPERIMENTAL
Intervention: FIMe (6‐FU, ICRF‐159 + methyl‐CCNU)
Number of subjects: 181
Study 7037163 — intervention group
Group type: EXPERIMENTAL
Intervention: FMe (5‐FU + methyl‐CCNU)
Number of subjects: 181
Study 31030995 — intervention group
Group type: EXPERIMENTAL
Intervention: Iclaprim 80 mg fixed dose
Number of subjects: 621
Study 31030995 — intervention group
Group type: COMPARATOR
Intervention: Vancomycin 15 mg/kg administered intravenously during 2 h every 12 h for 5–14 days
Number of subjects: 621
Study 31030995 — intervention group
Group type: EXPERIMENTAL
Intervention: Iclaprim
Number of subjects: 621
Study 31030995 — intervention group
Group type: COMPARATOR
Intervention: Vancomycin
Number of subjects: 621
Study 28608434 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D printed models of congenital cardiovascular lesions during a 20-minute lecture
Number of subjects: 0
Study 28608434 — intervention group
Group type: COMPARATOR
Intervention: Standard lecture on vascular rings and slings without 3D printed models
Number of subjects: 0
Study 25612845 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentalgon® (bilayer matrix type patch)
Number of subjects: 36
Study 25612845 — intervention group
Group type: COMPARATOR
Intervention: Durogesic SMAT (monolayer matrix type patch)
Number of subjects: 36
Study 25612845 — intervention group
Group type: COMPARATOR
Intervention: Fentalgon® and Durogesic SMAT
Number of subjects: 36
Study 24402597 — intervention group
Group type: EXPERIMENTAL
Intervention: Patch (13 cycles)
Number of subjects: 1504
Study 24402597 — intervention group
Group type: COMPARATOR
Intervention: Pill (6 cycles) followed by Patch (7 cycles)
Number of subjects: 1504
Study 24402597 — intervention group
Group type: EXPERIMENTAL
Intervention: Patch
Number of subjects: 1504
Study 24402597 — intervention group
Group type: COMPARATOR
Intervention: Pill
Number of subjects: 1504
Study 21536692 — intervention group
Group type: COMPARATOR
Intervention: Escitalopram (up to 20 mg/day) plus placebo
Number of subjects: 665
Study 21536692 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release bupropion (up to 400 mg/day) plus escitalopram (up to 20 mg/day)
Number of subjects: 665
Study 21536692 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release venlafaxine (up to 300 mg/day) plus mirtazapine (up to 45 mg/day)
Number of subjects: 665
Study 19139320 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital-based case manager
Number of subjects: 220
Study 19139320 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 220
Study 17762959 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl (25 mcg, titrated up to 50 mcg)
Number of subjects: 126
Study 17762959 — intervention group
Group type: COMPARATOR
Intervention: Midazolam (2 mg, titrated up to 5 mg)
Number of subjects: 126
Study 12757810 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes Mellitus and Peripheral Neuropathy (DM group)
Number of subjects: 40
Study 12757810 — intervention group
Group type: COMPARATOR
Intervention: Control group (without DM)
Number of subjects: 40
Study 10582668 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients initially thought to have had a stroke (misdiagnosed group)
Number of subjects: 224
Study 10582668 — intervention group
Group type: COMPARATOR
Intervention: Patients correctly diagnosed with brain tumors
Number of subjects: 224
Study 8739170 — intervention group
Group type: COMPARATOR
Intervention: NaF toothpaste and NaF mouthrinse
Number of subjects: 150
Study 8739170 — intervention group
Group type: EXPERIMENTAL
Intervention: AmF/SnF2 toothpaste and mouthrinse
Number of subjects: 150
Study 8739170 — intervention group
Group type: EXPERIMENTAL
Intervention: AmF/SnF2 toothpaste and NaF mouthrinse
Number of subjects: 150
Study 1908864 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (25 mg q 6hr)
Number of subjects: 12
Study 1908864 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of indomethacin and misoprostol (200 mcg q 6hr)
Number of subjects: 12
Study 1908864 — intervention group
Group type: COMPARATOR
Intervention: Misoprostol (200 mcg q 6hr)
Number of subjects: 12
Study 6981965 — intervention group
Group type: EXPERIMENTAL
Intervention: Dulcolax (bisacodyl) plus 2 L tapwater enema
Number of subjects: 1435
Study 6981965 — intervention group
Group type: EXPERIMENTAL
Intervention: Dulcolax or castor oil or X‐Prep, each with 2 L water enema
Number of subjects: 1435
Study 6981965 — intervention group
Group type: COMPARATOR
Intervention: Water enema only or castor oil only
Number of subjects: 1435
Study 30037692 — intervention group
Group type: EXPERIMENTAL
Intervention: CAD-CAM systems (group L, group iT, group C)
Number of subjects: 10
Study 30037692 — intervention group
Group type: COMPARATOR
Intervention: Conventional workflow (group K)
Number of subjects: 10
Study 30037692 — intervention group
Group type: COMPARATOR
Intervention: Comparison of digital workflow vs conventional workflow
Number of subjects: 10
Study 28673265 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone replacement therapy
Number of subjects: 70
Study 28673265 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 25924969 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine plus erlotinib (150 mg/day)
Number of subjects: 255
Study 25924969 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine plus erlotinib (150 mg/day)
Number of subjects: 255
Study 23746663 — intervention group
Group type: EXPERIMENTAL
Intervention: Pop-up alerts
Number of subjects: 902
Study 23746663 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacy intervention
Number of subjects: 902
Study 23746663 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician alert list
Number of subjects: 902
Study 23746663 — intervention group
Group type: EXPERIMENTAL
Intervention: EHR section
Number of subjects: 902
Study 22031172 — intervention group
Group type: EXPERIMENTAL
Intervention: Anacetrapib co-administered with digoxin
Number of subjects: 0
Study 22031172 — intervention group
Group type: COMPARATOR
Intervention: Digoxin alone
Number of subjects: 0
Study 20380111 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous pantoprasole (continuous regimen: 5 x 40 mg in continuous infusion of 8 mg/h for 72 h)
Number of subjects: 69
Study 20380111 — intervention group
Group type: COMPARATOR
Intervention: Standard regimen (40 mg bolus of PPI twice daily for 3 days)
Number of subjects: 69
Study 20380111 — intervention group
Group type: COMPARATOR
Intervention: Standard regimen
Number of subjects: 69
Study 20380111 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive regimen
Number of subjects: 69
Study 17130943 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 8 mg IV (Group 1, n=40)
Number of subjects: 120
Study 17130943 — intervention group
Group type: COMPARATOR
Intervention: Droperidol 1.25 mg IV (Group 2, n=40)
Number of subjects: 120
Study 17130943 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 2 mg IV (Group 3, n=40)
Number of subjects: 120
Study 15446660 — intervention group
Group type: EXPERIMENTAL
Intervention: Sentences with punctuation (commas)
Number of subjects: 88
Study 15446660 — intervention group
Group type: COMPARATOR
Intervention: Sentences without punctuation
Number of subjects: 88